Commonly used PGT testing solutions:
Advancements in next-generation sequencing (NGS) methods enable simple, scalable, and innovative sample-to-answer workflow solutions for PGT-A and PGT-M. NGS delivers fast results from precious samples, without the complexities that come with traditional genetic analysis tools.
Hear what your peers are saying about NGS and preimplantation genetic testing:
Catherine Welch provides an embryologist’s perspective on workflow, no results, rebiopsy, and mosaicism during preimplantation genetic testing for aneuploidy (PGT-A).
|Catherine Welch, MBA, TS(ABB)
Founder and Managing Director, Sequence46
Gary Nakhuda provides a clinical perspective on the benefits, current limitations, and unresolved issues in preimplantation genetic testing for aneuploidy (PGT-A).
|Gary Nakhuda, MD, FACOG
Co-Founder and Co-Director, Olive Fertility Centre, Canada
Emily Mounts discusses current challenges faced by genetic counselors in preimplantation genetic testing for aneuploidy (PGT-A).
|Emily Mounts, MS, CGC
Fertility Genetic Counselor, Focus Genetic Consulting
Conventional fertility centers usually combine two core divisions, the clinical department, and the embryology (andrology) laboratory. Currently, more centers choose to incorporate the third division, a genetic laboratory, into their IVF treatments for providing in-house service of molecular based experiments. Among these testing services, preimplantation genetic testing for aneuploidy (PGT-A) applied in embryo selection is the most widely used. Since 2014, next generation sequencing (NGS) has become the major platform for comprehensive chromosome screening (CCS). This talk would introduce the setting of a NGS workflow in a private fertility center, and how to make the entire process more convenient, efficient, and reliable with step-by-step modifications.
|Ms. Andrea Tzu-Hsuan Chuang, M.Sc.
Director of NGS Lab,
Stork Fertility Center, Taiwan
Integrated sequencing technology has enabled the use of both the PGT-A and PGT-M simultaneously. Reports have documented that the embryos screened for aneuploidy as well as for single gene or monogenic disorders, using the integrated technique of PGT-A and PGT-M have successfully improved the pregnancy rates from 45% to 70%.
|Dr. Alpana Razdan, Ph.D.
Vice President and Head of Lab Services,
Genestrings Diagnostic Centre Pvt Ltd., India
Learn the powerful benefits of running in-house PGT-A and PGT-M on the same NGS platform, with a single embryo biopsy. In-house control creates flexibility to respond to each patient scenario, thereby reducing unnecessary costs and time. And combining analyses from the same sample limits impact to the embryo, while producing comprehensive findings for greatest probability of pregnancy success and genetically healthy offspring.
Tee Sze Tian, MSc Clinical Embryology Group Chief Embryologist
TMC Fertility Centre
Follow the decision-making process and adoption of expanded carrier screening (ECS) and preimplantation genetic testing (PGT-A (aneuploidy) and PGT-M (monogenic) in patient care and reproductive genetics research labs.
Two presentations, followed by combined Q&A, cover:
Dr Murat Cetinkaya, PhD
Istanbul Memorial Hospital Assisted Reproductive Technologies and Reproductive Genetic Center
Prof Volkan Baltaci, MD, PhD
CEO, Mikrogen Reproductive Genetics Company
Our presenters, Alain Rico and Matt Osentoski, will take you through the requirements needed to add NGS to your laboratory. This will include space requirements, equipment, personnel, and validation steps.